Lung Cancer and Interstitial Lung Diseases

Area of Science:

• Oncology
• Pulmonology
• Radiology

Background:

• Lung cancer remains a leading cause of cancer death globally.
• Interstitial lung disease (ILD) and lung cancer share common risk factors, including smoking and genetic predispositions.
• The co-occurrence of ILD complicates lung cancer diagnosis and management, increasing risks of treatment-related toxicities.

Purpose of the Study:

• To explore the complex interplay between lung cancer and ILD.
• To highlight diagnostic and therapeutic challenges in managing patients with both conditions.
• To emphasize the need for improved management strategies and evidence-based treatments.

Main Methods:

• Review of existing literature on lung cancer and ILD.
• Analysis of shared risk factors and their impact.
• Discussion of diagnostic challenges, including radiological interpretation.
• Examination of treatment-related toxicities and limited evidence-based options.

Main Results:

• ILD presence complicates lung cancer diagnosis and treatment.
• Patients with ILD are more susceptible to treatment toxicities like pneumonitis and acute exacerbations.
• Limited evidence from large trials exists for optimal treatment strategies.
• The role of antifibrotic therapy in preventing pulmonary toxicity is still under investigation.

Conclusions:

• The interplay between lung cancer and ILD presents significant clinical challenges.
• There is a critical need for more robust clinical trials to guide treatment decisions.
• Emerging diagnostic tools, biomarkers, and personalized medicine are crucial for improving outcomes in this patient population.